InterCure Ltd. (INCR)
NASDAQ: INCR · Real-Time Price · USD
1.520
-0.070 (-4.40%)
May 12, 2025, 4:00 PM - Market closed
InterCure Revenue
In the year 2024, InterCure had annual revenue of 238.85M ILS, down -32.82%. InterCure had revenue of 125.73M in the half year ending June 30, 2024, a decrease of -31.11%.
Revenue (ttm)
238.85M ILS
Revenue Growth
-32.82%
P/S Ratio
1.15
Revenue / Employee
884,611 ILS
Employees
270
Market Cap
75.33M USD
Revenue Chart
* This company reports financials in ILS.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 238.85M | -116.71M | -32.82% |
Dec 31, 2023 | 355.55M | -33.13M | -8.52% |
Dec 31, 2022 | 388.68M | 169.01M | 76.93% |
Dec 31, 2021 | 219.68M | 154.64M | 237.78% |
Dec 31, 2020 | 65.04M | 56.11M | 628.60% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
INCR News
- 11 days ago - InterCure Announces FY2024 Results and Provides Q1 2025 Update: Revenue of NIS 239 Million and Adjusted EBITDA of NIS 24 Million, Strong Start to 2025 - PRNewsWire
- 3 months ago - InterCure Names Alexander Rabinovich as Chairman Replacing Ehud Barak - PRNewsWire
- 5 months ago - InterCure has Secured Funding of NIS 66M to support the recovery of Nir Oz Facility - PRNewsWire
- 8 months ago - Are Investors Missing The Forest? 35% Stock Drop Masks The International Potential Of This Weed Company - Benzinga
- 9 months ago - InterCure Announces First Half of 2024 Results: Revenue of NIS 126 million and Adjusted EBITDA of NIS 21 million - GlobeNewsWire
- 9 months ago - InterCure Announces Expansion of its Strategic partnership with Cookies to Germany - Business Wire
- 11 months ago - InterCure: A Cannabis Industry Leader Still Flying Under The Radar - Seeking Alpha
- 1 year ago - InterCure to Participate in Canaccord Genuity's 8th Annual Global Cannabis Conference - Business Wire